This Crypto Coin Could 10x FASTER Than Bitcoin

A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move is being made in preparation to onboard all of Sony products (including Sony's Playstation, which captured a record 62% share of the global gaming console market in 2024). Enthusiasts and experts are buzzing with anticipation qnd one little-known crypto coin is poised for RAPID growth as we see this all unfold.

Click here to review my research and unique strategy to score potential profits from this under-the-

Greg Zante Biography and Net Worth

CFO of Viking Therapeutics

Greg Zante serves as our Chief Financial Officer. Mr. Zante possesses nearly 25 years of financial management experience at public and private companies in the biotechnology and accounting industries and most recently served as Viking’s senior vice president of finance. Prior to joining Viking, Mr. Zante was Chief Financial Officer at Dance Biopharm, a diabetes-focused biopharmaceutical company, where he managed the company’s private financing strategy and positioned it for initial public offering activities. Mr. Zante has also previously held senior positions at several biopharmaceutical companies including Sangamo Therapeutics, Calyx Therapeutics and Matrix Pharmaceuticals. He is a certified public accountant in the state of California and has previously served as a senior staff accountant at Ernst & Young. Mr. Zante received his bachelor’s degree in business-economics from the University of California, Los Angeles.

What is Greg Zante's net worth?: The estimated net worth of Greg Zante is at least $11.67 million as of May 3rd, 2024. Mr. Zante owns 174,854 shares of Viking Therapeutics stock worth more than $11,668,007 as of September 16th. This net worth approximation does not reflect any other investments that Mr. Zante may own. Additionally, Mr. Zante receives an annual salary of $655,000.00 as CFO at Viking Therapeutics. Learn More about Greg Zante's net worth.
How old is Greg Zante?: Mr. Zante is currently 53 years old. There are 3 older executives and no younger executives at Viking Therapeutics. The oldest executive at Viking Therapeutics is Ms. Marianne Mancini, Chief Operating Officer, who is 59 years old. Learn More on Greg Zante's age.
What is Greg Zante's salary?: As the CFO of Viking Therapeutics, Inc., Mr. Zante earns $655,000.00 per year. There are 2 executives that earn more than Mr. Zante. The highest earning executive at Viking Therapeutics is Dr. Brian Lian Ph.D., President, CEO & Director, who commands a salary of $987,100.00 per year. Learn More on Greg Zante's salary.
How do I contact Greg Zante?: The corporate mailing address for Mr. Zante and other Viking Therapeutics executives is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. Viking Therapeutics can also be reached via phone at (858) 704-4660 and via email at [email protected]. Learn More on Greg Zante's contact information.
Has Greg Zante been buying or selling shares of Viking Therapeutics?: Greg Zante has not been actively trading shares of Viking Therapeutics within the last three months. Most recently, Greg Zante sold 66,756 shares of the business's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $74.69, for a transaction totalling $4,986,005.64. Following the completion of the sale, the chief financial officer now directly owns 174,854 shares of the company's stock, valued at $13,059,845.26. Learn More on Greg Zante's trading history.
Who are Viking Therapeutics' active insiders?: Viking Therapeutics' insider roster includes Matthew Foehr (Director), Brian Lian (CEO), Lawson Macartney (Director), Marianna Mancini (COO), Sarah Rouan (Director), Charles Rowland, Jr. (Director), J. Matthew Singleton (Director), Greg Zante (CFO), Greg Zante (CFO), and Greg Zante (CFO). Learn More on Viking Therapeutics' active insiders.
Are insiders buying or selling shares of Viking Therapeutics?: In the last year, insiders at the biotechnology company sold shares 14 times. They sold a total of 1,012,501 shares worth more than $54,639,024.05. The most recent insider tranaction occured on August, 21st when CEO Brian Lian sold 1,000 shares worth more than $69,900.00. Insiders at Viking Therapeutics own 4.7% of the company. Learn More about insider trades at Viking Therapeutics.
Information on this page was last updated on 8/21/2024.

Greg Zante Insider Trading History at Viking Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2024	Sell	66,756	$74.69	$4,986,005.64	174,854
1/4/2024	Sell	15,000	$17.90	$268,500.00	180,730
4/17/2023	Sell	7,500	$20.00	$150,000.00	149,279
4/11/2023	Sell	56,295	$18.00	$1,013,310.00	149,279
4/3/2023	Sell	30,911	$18.00	$556,398.00	147,778
3/30/2023	Sell	131,029	$17.00	$2,227,493.00	147,778

Greg Zante Buying and Selling Activity at Viking Therapeutics

Viking Therapeutics Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $67.18

$64.54

$68.83

50 Day Range

MA: $58.00

$49.84

$66.73

2 Week Range

Now: $67.18

$8.28

$99.41

Volume

2,251,866 shs

Average Volume

4,548,935 shs

Market Capitalization

$7.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

This Crypto Coin Could 10x FASTER Than Bitcoin

From Crypto 101 Media | Ad

Click here to review my research and unique strategy to score potential profits from this under-the-

Greg Zante Biography and Net Worth

What is Greg Zante's net worth?

How old is Greg Zante?

What is Greg Zante's salary?

How do I contact Greg Zante?

Has Greg Zante been buying or selling shares of Viking Therapeutics?

Who are Viking Therapeutics' active insiders?

Are insiders buying or selling shares of Viking Therapeutics?